Hikma Pharmaceuticals told shareholders its year had begun with an "encouraging start" on Friday, as they gathered for the annual general meeting, with the global Injectables business particularly said to be performing "well". The FTSE 250 drugmaker said that in the US, the breadth of the injectables product portfolio, enhanced by six product launches in the year to date, was enabling the company to meet increased demand across its marketed portfolio. That demand was more than offsetting ...Den vollständigen Artikel lesen ...